Felix Lourdes 4

What Happened
Felix Lourdes, a director of Lixte Biotechnology Holdings, received an award of 25,000 restricted stock units (RSUs) on April 15, 2026 in exchange for the cancellation of 25,000 stock options. The RSUs vest immediately and each RSU represents a contingent right to one share upon vesting. No purchase price or sale proceeds are reported (prices listed as N/A).

Key Details

• Transaction date: April 15, 2026 (Form 4 filed April 17, 2026 — timely).
• Reported transactions: Award/Acquisition (code A) — 25,000 RSUs; Disposition to issuer (code D, derivative) — cancellation of 25,000 options.
• Price/Value: Not reported (N/A) for both transactions.
• Shares owned after transaction: The filing does not disclose Lourdes’s total shares owned after these transactions.
• Footnotes: The options were canceled pursuant to a Stock Option Cancellation Agreement dated April 15, 2026 in exchange for 25,000 RSUs that vest immediately (each RSU converts to one share upon vesting). The canceled options had previously provided for 50% vesting at grant and the remaining 50% vesting in quarterly installments beginning March 31, 2026.

Context
RSUs are a form of equity compensation that entitle the holder to receive shares upon vesting; because these RSUs vest immediately, the grant effectively confers a right to 25,000 shares subject to any settlement or transfer restrictions. This filing reflects a substitution of equity compensation (options → RSUs) rather than a market purchase or sale; such awards are common as part of executive/director compensation and do not by themselves indicate a buy or sell opinion by the insider.